Title: Neovastat® (AEterna)
CAS Registry Number: 305838-77-1
Manufacturers' Codes: AE-941
Literature References: Naturally occurring antiangiogenic agent derived by ultrafiltration of liquid shark cartilage; composed of the molecular fraction below 500 kD. Exhibits multiple mechanisms of action: matrix metalloproteinases (MMP) inhibition, VEGF receptor binding inhibition, induction of endothelial cell apoptosis, and increased tissue-type plasminogen activator (tPA) production. Prepn from spiny dog fish (Squalus acanthias): E. Dupont et al., WO 9532722; eidem, US 5985839 (1995, 1999 both to AEterna); and antiangiogenic activity: eidem, J. Cutan. Med. Surg. 2, 146 (1998). Mechanism of action studies: R. BĂ©liveau et al., Clin. Cancer Res. 8, 1242 (2002); D. Gingras et al., Invest. New Drugs 22, 17 (2004). Clinical evaluation in plaque psoriasis: D. N. Sauder et al., J. Am. Acad. Dermatol. 47, 535 (2002); in lung cancer: J. Latreille et al., Clin. Lung Cancer 4, 231 (2003). Purifn of tPA stimulating component: D. Boivin et al., Arch. Biochem. Biophys. 431, 197 (2004). Reviews of pharmacology and clinical development: R. M. Bukowski, Expert Opin. Invest. Drugs 12, 1403-1411 (2003); K. Dredge, Curr. Opin. Invest. Drugs 5, 668-677 (2004).
Therap-Cat: Antineoplastic; antipsoriatic.

Others monographs:
GadoversetamideShellolic AcidPyrazinoic AcidDibutyl Succinate
Aluminum OxalateBenzoyl Chloride3-O-Lauroylpyridoxol DiacetateFerbam
Fluperolone AcetateResin ScammonyZinc CarbonateSinapultide
©2016 DrugLead US FDA&EMEA